Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771067 | 0.92 | HSD17B10 (0.43) | SMN1; SMN2HSD17B10OPRD1ALOX5APFEN1 | |
| SCHEMBL29039261 | 0.92 | HSD17B10 (0.43) | SMN1; SMN2HSD17B10OPRD1ALOX5APFEN1 | |
| SCHEMBL2490765 | 0.92 | HSD17B10 (0.43) | SMN1; SMN2HSD17B10OPRD1ALOX5APFEN1 | |
| SCHEMBL3763846 | 0.88 | PDE8B (0.43) | SMN1; SMN2HSD17B10OPRD1ALOX5APFEN1 | |
| SCHEMBL2566481 | 0.86 | HSD17B10 (0.38) | SMN1; SMN2HSD17B10LMNAALOX5APFEN1 | |
| SCHEMBL3832136 | 0.86 | HSD17B10 (0.38) | SMN1; SMN2HSD17B10LMNAALOX5APFEN1 | |
| SCHEMBL3781276 | 0.83 | HSD17B10 (0.36) | SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL3781269 | 0.83 | HSD17B10 (0.36) | SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL2567398 | 0.83 | HSD17B10 (0.34) | SMN1; SMN2HSD17B10USP2NPC1 | |
| SCHEMBL6318180 | 0.82 | KMT2A (0.43) | SMN1; SMN2HSD17B10LMNANPSR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | SMN1; SMN2 3016/4885HSD17B10 3097/4885LMNA 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.